BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan

  November 19, 2025

   · 

  5 min read
• Press Releases

  Cellugy Welcomes Former Estée Lauder Executive Steven Schnittger to Board of Directors

  November 19, 2025

   · 

  3 min read
• Press Releases

  Keros Therapeutics Announces Preliminary Results of Tender Offer

  November 19, 2025

   · 

  4 min read
• Press Releases

  Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

  November 19, 2025

   · 

  4 min read
• Press Releases

  Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025

  November 19, 2025

   · 

  12 min read
• Press Releases

  Fluid Biomed Appoints Veteran MedTech Executive John Kilcoyne as Independent Board Chair

  November 19, 2025

   · 

  2 min read
• Press Releases

  Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery

  November 19, 2025

   · 

  2 min read
• Press Releases

  European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

  November 19, 2025

   · 

  19 min read
• Press Releases

  Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

  November 19, 2025

   · 

  16 min read
• 

  Mergers & acquisitions

  UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck

  Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to go with its original suitor.

  November 19, 2025

   · 

  3 min read

   · 

  Tristan Manalac